CN110636862B - 用于治疗乳腺癌的组合疗法 - Google Patents
用于治疗乳腺癌的组合疗法Info
- Publication number
- CN110636862B CN110636862B CN201880030008.9A CN201880030008A CN110636862B CN 110636862 B CN110636862 B CN 110636862B CN 201880030008 A CN201880030008 A CN 201880030008A CN 110636862 B CN110636862 B CN 110636862B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- amino
- palbociclib
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472345P | 2017-03-16 | 2017-03-16 | |
| US62/472,345 | 2017-03-16 | ||
| PCT/US2018/022961 WO2018170447A1 (en) | 2017-03-16 | 2018-03-16 | Combination therapies for the treatment of breast cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110636862A CN110636862A (zh) | 2019-12-31 |
| CN110636862B true CN110636862B (zh) | 2026-03-20 |
Family
ID=61874039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880030008.9A Active CN110636862B (zh) | 2017-03-16 | 2018-03-16 | 用于治疗乳腺癌的组合疗法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11083722B2 (enExample) |
| EP (2) | EP4218820A3 (enExample) |
| JP (1) | JP7219224B2 (enExample) |
| KR (1) | KR102517650B1 (enExample) |
| CN (1) | CN110636862B (enExample) |
| AU (1) | AU2018234903B2 (enExample) |
| BR (1) | BR112019019261A2 (enExample) |
| CA (1) | CA3056701A1 (enExample) |
| IL (1) | IL269357B2 (enExample) |
| MA (1) | MA47776A (enExample) |
| MX (1) | MX2019010981A (enExample) |
| RU (1) | RU2764724C2 (enExample) |
| SG (1) | SG11201908531WA (enExample) |
| WO (1) | WO2018170447A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX385930B (es) * | 2016-11-28 | 2025-03-18 | Eisai R&D Man Co Ltd | Sales de derivado de indazol y cristales de las mismas. |
| SG11202005937QA (en) | 2018-01-08 | 2020-07-29 | G1 Therapeutics Inc | G1t38 superior dosage regimes |
| JP2023548340A (ja) * | 2020-11-06 | 2023-11-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 乳癌の治療方法 |
| CN113018357A (zh) * | 2021-02-08 | 2021-06-25 | 湖南农业大学 | 茶多酚和帕博西尼联合在制备治疗乳腺癌的制剂中的用途 |
| WO2024115680A1 (en) | 2022-12-01 | 2024-06-06 | Krka, D.D., Novo Mesto | Ribociclib salts and formulations thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016196337A1 (en) * | 2015-05-29 | 2016-12-08 | Eisai R & D Management Co., Ltd. | Tetrasubstituted alkene compounds and their use |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6399633B1 (en) | 1999-02-01 | 2002-06-04 | Aventis Pharmaceuticals Inc. | Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation |
| DE19959546A1 (de) | 1999-12-09 | 2001-06-21 | Rhone Poulenc Rorer Gmbh | Pharmazeutische Zubereitung zur Behandlung von Tumorerkrankungen |
| JP2003520798A (ja) | 2000-01-18 | 2003-07-08 | アベンテイス・フアーマシユーチカルズ・インコーポレーテツド | （−）−シス−２−（２−クロロフェニル）−５，７−ジヒドロキシ−８［４ｒ−（３ｓ−ヒドロキシ−１−メチル）ピペリジニル］−４ｈ−１−ベンゾピラン−４−オンのエタノール溶媒化合物 |
| EA005247B1 (ru) | 2000-01-18 | 2004-12-30 | Авентис Фармасьютикалз Инк. | Псевдополиморф (-)-цис-2-(2-хлорфенил)-5,7-дигидрокси-8[4r-(3s-гидрокси-1-метил)пиперидинил]-4h-1-бензопиран-4-она |
| WO2002022133A1 (en) | 2000-09-12 | 2002-03-21 | Virginia Commonwealth University | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents |
| ATE314370T1 (de) | 2002-01-22 | 2006-01-15 | Warner Lambert Co | 2-(pyridin-2-ylamino)-pyrido(2,3-d)pyrimidin-7- one |
| WO2005012256A1 (en) | 2003-07-22 | 2005-02-10 | Astex Therapeutics Limited | 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
| AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| US20080161355A1 (en) | 2005-01-21 | 2008-07-03 | Astex Therapeutics Limited | Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents |
| US20080161251A1 (en) | 2005-01-21 | 2008-07-03 | Astex Therapeutics Limited | Pharmaceutical Compounds |
| CA2594477C (en) | 2005-01-21 | 2016-07-12 | Astex Therapeutics Limited | Pharmaceutical compounds |
| JP2008255008A (ja) | 2005-07-19 | 2008-10-23 | Tokyo Medical & Dental Univ | 滑膜細胞増殖抑制剤 |
| US7776832B2 (en) | 2006-04-21 | 2010-08-17 | Gem Pharmaceuticals, Llc | Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines |
| JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
| US20110159111A1 (en) | 2006-06-29 | 2011-06-30 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US20090263398A1 (en) | 2006-07-14 | 2009-10-22 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US20100021420A1 (en) | 2006-07-14 | 2010-01-28 | Astex Therapeutics Limited | Combinations of pyrazole derivatives for the inhibition of cdks and gsk's |
| US20090318430A1 (en) | 2006-07-21 | 2009-12-24 | Astex Therapeutics Limited | Medical use of cyclin dependent kinases inhibitors |
| US7902147B2 (en) | 2007-11-05 | 2011-03-08 | Duke University | Chronic lymphocytic leukemia prognosis and treatment |
| EA019094B1 (ru) | 2008-08-22 | 2014-01-30 | Новартис Аг | Пирролопиримидины и их применение |
| PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| UY33226A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 |
| KR101830455B1 (ko) | 2010-04-13 | 2018-02-20 | 노파르티스 아게 | 시클린 의존성 키나제 ４ 또는 시클린 의존성 키나제 （ｃｄｋ４／６） 억제제 및 ｍｔｏｒ 억제제를 포함하는 암 치료를 위한 조합물 |
| GB2483736B (en) * | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| CN103429243B (zh) | 2010-10-25 | 2016-06-08 | G1治疗公司 | Cdk抑制剂 |
| US20120115878A1 (en) | 2010-11-10 | 2012-05-10 | John Vincent Calienni | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
| DK2937349T3 (en) | 2011-03-23 | 2017-02-20 | Amgen Inc | CONDENSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 |
| BR112015012197A8 (pt) | 2012-11-28 | 2019-10-01 | Novartis Ag | usos de inibidores de cdk mtor, e combinação farmacêutica compreendendo os mesmos |
| CA2906166C (en) | 2013-03-15 | 2023-03-14 | G1 Therapeutics, Inc. | Hspc-sparing treatments for rb-positive abnormal cellular proliferation |
| SI3033086T1 (sl) | 2013-08-14 | 2022-01-31 | Novartis Ag | Kombinirana terapija za zdravljenje raka |
| AU2015228859A1 (en) | 2014-03-13 | 2016-07-07 | F. Hoffmann-La Roche Ag | Therapeutic combinations with estrogen receptor modulators |
| WO2016025650A1 (en) | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| CN104529904B (zh) | 2015-01-09 | 2016-08-31 | 苏州明锐医药科技有限公司 | 玻玛西尼的制备方法 |
| WO2016126889A1 (en) | 2015-02-03 | 2016-08-11 | G1 Therapeutics, Inc. | Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy |
| KR102676629B1 (ko) * | 2015-04-29 | 2024-06-18 | 래디어스 파마슈티컬스, 인코포레이티드 | 암을 치료하는 방법 |
-
2018
- 2018-03-16 BR BR112019019261-1A patent/BR112019019261A2/pt not_active Application Discontinuation
- 2018-03-16 CN CN201880030008.9A patent/CN110636862B/zh active Active
- 2018-03-16 EP EP23159590.1A patent/EP4218820A3/en not_active Withdrawn
- 2018-03-16 AU AU2018234903A patent/AU2018234903B2/en active Active
- 2018-03-16 KR KR1020197029851A patent/KR102517650B1/ko active Active
- 2018-03-16 WO PCT/US2018/022961 patent/WO2018170447A1/en not_active Ceased
- 2018-03-16 MA MA047776A patent/MA47776A/fr unknown
- 2018-03-16 CA CA3056701A patent/CA3056701A1/en active Pending
- 2018-03-16 SG SG11201908531W patent/SG11201908531WA/en unknown
- 2018-03-16 IL IL269357A patent/IL269357B2/en unknown
- 2018-03-16 EP EP18715441.4A patent/EP3595725B1/en active Active
- 2018-03-16 MX MX2019010981A patent/MX2019010981A/es unknown
- 2018-03-16 RU RU2019132893A patent/RU2764724C2/ru active
- 2018-03-16 JP JP2019550800A patent/JP7219224B2/ja active Active
- 2018-03-16 US US16/493,931 patent/US11083722B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016196337A1 (en) * | 2015-05-29 | 2016-12-08 | Eisai R & D Management Co., Ltd. | Tetrasubstituted alkene compounds and their use |
Non-Patent Citations (2)
| Title |
|---|
| Joseph Leha＇r等.Synergistic drug combinations tend to improve therapeutically relevant selectivity.《NATURE BIOTECHNOLOGY》.2009, * |
| Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer;Andrea Rocca et al.;《Expert Opin Pharmacother》;20140215;第415页右栏 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018170447A1 (en) | 2018-09-20 |
| US11083722B2 (en) | 2021-08-10 |
| RU2764724C2 (ru) | 2022-01-19 |
| RU2019132893A (ru) | 2021-04-16 |
| AU2018234903B2 (en) | 2024-02-08 |
| MX2019010981A (es) | 2020-09-07 |
| EP3595725B1 (en) | 2023-05-03 |
| JP7219224B2 (ja) | 2023-02-07 |
| EP3595725A1 (en) | 2020-01-22 |
| US20210113537A1 (en) | 2021-04-22 |
| CA3056701A1 (en) | 2018-09-20 |
| KR102517650B1 (ko) | 2023-04-05 |
| RU2019132893A3 (enExample) | 2021-06-24 |
| EP4218820A2 (en) | 2023-08-02 |
| EP4218820A3 (en) | 2023-09-20 |
| IL269357B2 (en) | 2024-10-01 |
| CN110636862A (zh) | 2019-12-31 |
| AU2018234903A1 (en) | 2019-10-10 |
| IL269357A (en) | 2019-11-28 |
| JP2020510075A (ja) | 2020-04-02 |
| SG11201908531WA (en) | 2019-10-30 |
| MA47776A (fr) | 2020-01-22 |
| KR20190125448A (ko) | 2019-11-06 |
| IL269357B1 (en) | 2024-06-01 |
| BR112019019261A2 (pt) | 2020-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7219224B2 (ja) | 乳癌の治療のための組合せ療法 | |
| CN109803684B (zh) | 用于治疗肝细胞癌的组合疗法 | |
| JP7665700B2 (ja) | 肝細胞癌の治療のための併用療法 | |
| US20230321110A1 (en) | Combination therapy of a raf inhibitor and a mek inhibitor for the treatment of sarcoma | |
| JP2019515010A (ja) | 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ | |
| JP7497353B2 (ja) | Ｅｓｒ１変異を含むモデルにおいて癌を治療するための方法 | |
| RU2787993C2 (ru) | Комбинированные терапии для лечения гепатоцеллюлярной карциномы | |
| NZ737544A (en) | Micronized compound a, compositions and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |